Yuekang Pharmaceutical: Subsidiary injection approved for FDA clinical trials

YueKang Pharmaceutical announced that its subsidiary YueKang Science and Technology's YKYY13 injection recently received approval from the US FDA for clinical trials, aimed at treating chronic hepatitis B virus infection. YKYY13 injection is a double-stranded siRNA drug independently developed by YueKang Science and Technology and Hangzhou Tianlong Pharmaceutical, designed to inhibit HBV replication and pathogenic protein production through RNA interference, thereby achieving functional cure of HBV. Preclinical studies have shown significant HBV inhibition activity of the drug in vitro and in vivo, with good safety and tolerability in animal experiments. FDA approval signifies a milestone in the drug development process, but the company warns investors that drug development involves uncertainties.